Cellectar Biosciences' Stock Price Adjusted to $18 by Roth Capital

Roth Capital adjusts its target price for Cellectar Biosciences to $18 from $3, citing the company's reverse stock split. Despite the change, the firm maintains a Buy rating on the shares.

Roth Capital Partners has revised its target price for Cellectar Biosciences (CLRB) to $18 from $3, citing the company's recent reverse stock split. Despite the significant adjustment, the firm maintains a Buy rating on the shares. The move reflects Roth Capital's optimism about Cellectar Biosciences' potential and its commitment to the company's long-term prospects.

Cellectar Biosciences, a late-stage clinical biopharmaceutical company, focuses on the development of phospholipid drug conjugates (PDCs) for cancer treatment and imaging. Its portfolio includes CLR 131, CLR 125, CLR 124, and CLR 1502, each targeting various types of cancer. The company is scheduled to release its Q2 2025 earnings on August 14, with analysts expecting an EPS of $-3.66 [2].

The reverse stock split, which took effect on July 1, 2025, is designed to simplify Cellectar Biosciences' stock structure and potentially attract new investors. As of June 30, 2025, the company reported a GAAP EPS of -$3.39, beating the estimated -$3.70 by $0.31 [3]. The company also announced a one-for-thirty reverse stock split, which will reduce the number of outstanding shares from approximately 100 million to 3.33 million.

Roth Capital's decision to maintain a Buy rating indicates confidence in Cellectar Biosciences' pipeline and future prospects. The firm believes that the reverse stock split will enhance the company's liquidity and attractiveness to institutional investors. However, the stock has experienced a significant decline over the past 52 weeks, with a 92.69% decrease in share price [2].

Investors are encouraged to monitor Cellectar Biosciences' upcoming earnings release and any subsequent guidance for further insights into the company's performance and future prospects. As always, it is essential to conduct thorough research and consider multiple factors before making investment decisions.

References:
[1] https://www.cnn.com/markets/stocks/CLRB
[2] https://www.ainvest.com/news/cellectar-biosciences-q2-2025-earnings-preview-analysts-expect-3-66-eps-2508/
[3] https://seekingalpha.com/news/4485266-cellectar-biosciences-gaap-eps-of-3_39-beats-by-0_31